Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02546388 · ClinicalTrials.gov registry record · NA
Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis
A NA study, sponsored by Marcelo F. Di Carli, MD, FACC.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
NCT02546388 is a NA study that has completed, run by Marcelo F. Di Carli, MD, FACC. The registered enrollment target is 17 participants.
The verdict
NCT02546388, a NA study, has completed, sponsored by Marcelo F. Di Carli, MD, FACC.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this research study to find out if a drug called OctreoScan or DOTATATE can help doctors diagnose people with cardiac sarcoidosis better. OctreoScan and DOTATATE are both approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors.
Interventions
- DRUG Gallium-68 DOTATATE
- DRUG Indium-111 Pentreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2015-10 |
| Est. Completion | 2018-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02546388
The ClinicalTrials.gov registry entry for NCT02546388 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marcelo F. Di Carli, MD, FACC, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gallium-68 DOTATATE is the first listed.
NCT02546388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02546388 about?
NCT02546388 is a clinical study titled "Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis". The purpose of this research study to find out if a drug called OctreoScan or DOTATATE can help doctors diagnose people with cardiac sarcoidosis better. OctreoScan and DOTATATE are both approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors.
What is the current status of trial NCT02546388?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2015-10. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02546388?
The interventions under investigation include: Gallium-68 DOTATATE (DRUG), Indium-111 Pentreotide (DRUG).
Who is sponsoring clinical trial NCT02546388?
This trial is sponsored by Marcelo F. Di Carli, MD, FACC, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.